Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 25;100(17):e1799-e1811.
doi: 10.1212/WNL.0000000000207069. Epub 2023 Feb 15.

Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke

Junghee Ha  1 , Dong-Woo Choi  1 , Kwang Joon Kim  2 , Keun You Kim  2 , Chung Mo Nam  1 , Eosu Kim  2
Affiliations

Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke

Junghee Ha et al. Neurology. .

Abstract

Background and objectives: Previous studies have reported the protective effect of pioglitazone on dementia in patients with type 2 diabetes mellitus (DM). Recent studies have shown that pioglitazone also lowers the risk of primary and recurrent stroke. Understanding the characteristics of patients particularly associated with the benefits of pioglitazone would facilitate its personalized use by specifying subpopulations during routine clinical care. The aim of this study was to examine the effects of pioglitazone use on dementia in consideration of stroke occurrence.

Methods: Using nationwide longitudinal data of patients with DM from the Korean National Health Insurance Service DM cohort (2002-2017), we investigated the association of pioglitazone use with incident dementia in patients with new-onset type 2 DM. The heterogeneity of the treatment effect was examined using exploratory analyses. Using a multistate model, we assessed the extent to which incident stroke affects the association between pioglitazone use and dementia.

Results: Pioglitazone use was associated with a reduced risk of dementia, compared with nonuse (adjusted hazard ratio [aHR] = 0.84, 95% CI 0.75-0.95); the risk reduction in dementia was greater among patients with a history of ischemic heart disease or stroke before DM onset (aHR = 0.46, 95% CI 0.24-0.90; aHR = 0.57, 95% CI 0.38-0.86, respectively). The incidence of stroke was also reduced by pioglitazone use (aHR = 0.81, 95% CI 0.66-1.00). However, when the stroke developed during the observation period of pioglitazone use, such lowered risk of dementia was not observed (aHR = 1.27, 95% CI 0.80-2.04).

Discussion: Pioglitazone use is associated with a lower risk of dementia in patients with DM, particularly in those with a history of stroke or ischemic heart disease, suggesting the possibility of applying a personalized approach when choosing pioglitazone to suppress dementia in patients with DM.

PubMed Disclaimer

Conflict of interest statement

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Figures

Figure 1
Figure 1. Kaplan–Meier Cumulative Incidence of Dementia in Patients With Newly Diagnosed Type 2 Diabetes Mellitus
The red and gray lines indicate patients treated with and without pioglitazone, respectively.
See this image and copyright information in PMC

Comment in

References

    1. Umegaki H. Type 2 diabetes as a risk factor for cognitive impairment: current insights. Clin IntervAging. 2014;9:1011-1019. doi: 10.2147/cia.s48926. - DOI - PMC - PubMed
    1. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol. 2011;71(3):365-376. doi: 10.1111/j.1365-2125.2010.03830.x. - DOI - PMC - PubMed
    1. Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes. 2014;63(7):2253-2261. doi: 10.2337/db14-0287. - DOI - PMC - PubMed
    1. Combs CK, Bates P, Karlo JC, Landreth GE. Regulation of β-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor α. Neurochem Int. 2001;39(5-6):449-457. doi: 10.1016/s0197-0186(01)00052-3. - DOI - PubMed
    1. Searcy JL, Phelps JT, Pancani T, et al. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2012;30(4):943-961. doi: 10.3233/jad-2012-111661. - DOI - PMC - PubMed

Publication types

MeSH terms